QuidelOrtho Expands Portfolio With the Launch of FDA-Approved Test

QuidelOrtho (QDEL) has launched the FDA-approved QUICKVUE Influenza + SARS Test, a CLIA-waived rapid immunoassay designed for professional use that simultaneously detects influenza A, B, and SARS-CoV-2 antigens from a single sample within 10 minutes. This expansion of its respiratory solutions portfolio is expected to significantly boost QDEL's Molecular Diagnostics and Point of Care business units, capitalizing on the global point-of-care diagnostics market, which is projected to grow from $47.8 billion in 2024 to $68.5 billion by 2030. The test's ability to differentiate between flu and COVID-19 is anticipated to aid clinicians in making timely treatment decisions.

Analysis

QuidelOrtho (QDEL) has strategically expanded its respiratory diagnostics portfolio with the launch of its FDA-approved QUICKVUE Influenza + SARS Test. This 510(k)-cleared and CLIA-waived immunoassay differentiates between influenza A, influenza B, and SARS-CoV-2 from a single sample, delivering results within 10 minutes for professional use. The launch is timed to capitalize on the substantial global point-of-care diagnostics market, which is projected to grow from $47.8 billion in 2024 to $68.5 billion by 2030 at a 5.8% CAGR. This initiative is expected to directly bolster the company's Molecular Diagnostics and Point of Care business units, which already demonstrated robust revenue growth in the second quarter of 2025. While this development is a clear positive for QDEL, the company operates in a highly competitive environment. Peers such as Qiagen (QGEN) are advancing with new European certifications and system launches, while Hologic (HOLX) and Thermo Fisher (TMO) have also recently reported strong performance in their respective diagnostics divisions, indicating intense competition for market share.

Key Decisions for Investors

• This product launch represents a significant positive catalyst for QuidelOrtho, strengthening its competitive position ahead of the respiratory illness season and reinforcing its growth narrative within the high-value point-of-care diagnostics market.
• Investors should monitor QuidelOrtho's upcoming quarterly earnings for specific data on the uptake of the QUICKVUE Influenza + SARS Test and growth in the Molecular Diagnostics and Point of Care segments to validate the commercial success of this launch.
• While the launch is a positive development, it is critical to continue tracking the product pipelines and market penetration of key competitors like Qiagen, Hologic, and Thermo Fisher, as their innovations could impact QuidelOrtho's ability to capture its targeted market share.